Abstract
AbstractNeuromyelitis optica spectrum disorders are rare relapsing inflammatory central nervous system diseases with a heterogenous immunological and clinical spectrum. International collaborations are required to: (i) reach a better understanding of the disease and its subtypes; (ii) develop laboratory and imaging biomarkers; and (iii) ultimately improve treatments.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
